Loading
Swedish Orphan Biovitrum AB (publ) Stock: price and insider trades · Sweden
5 insiders bought €11.0M of shares over the last 90 days, the latest by Katy Mazibuko, filed 17 Aug 2026.
Insider Decl.
445
Thresholds
n/a
Buy Volume
€86M
190 ops. · all time
Sell Volume
€140M
134 ops. · all time
Who traded when
BuySaleGuido Oelkers9 buys9 sales
Daniel Rankin3 buys6 sales
Duane Barnes3 buys5 sales
Christin Wesström3 buys4 sales
Norbert Oppitz3 buys4 sales
Mahmood Ladha2 buys4 sales
+10 other insiders
Analyst consensus: bullish or bearish?
Analysts rate Swedish Orphan Biovitrum AB (publ) Buy (bullish), based on 12 analysts. Average price target: SEK 502.50.
Fundamental score
Ranked 14,200 of 26,284 companies
49.1
score / 100
Value41
Quality57
FCF yld3.4%
Earn yld0.3%
EV/EBITDA15.5x
ROE3.4%
Gross mgn78%
Net mgn1.7%
Debt/EBITDA1.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
SEK 446.60
Analyst consensus
12 analystsBuy
SEK 350.00Target SEK 502.50(+13%)SEK 590.00
Income statement
RevenueSEK 28.2B
Gross profitSEK 22B78% margin
EBITDASEK 10.9B39% margin
Net incomeSEK 478M4.5% margin
Valuation
PER (trailing)118.8x
PER (forward)18.7x
P/Book3.7x
Beta0.36
Balance sheet & cash
Market capSEK 155.4B
Total debtSEK 11.5B
Free Cash FlowSEK 5.4B
Debt / Equity42%
Profitability & ownership
ROE3.4%
ROA7.7%
% insiders9.8%
% institutions76.5%
Last declaration on 17 August 2026
Declarations445 total
56 shares@ SEK 441.9970.0000% mcap100.0% of flowAktieISIN SE0000872095FI:csv-f5ac90647387c5924fe4
Canonical exit: 10 Nov 2026 (T+90)
79,208 shares@ SEK 235.150.013% mcap8.0% of flowAktieISIN SE0000872095FI:csv-41b267e5dd511348c69c
Canonical exit: 29 Oct 2026 (T+90)
79,208 shares@ SEK 467.410.025% mcap15.7% of flowAktieISIN SE0000872095FI:csv-3a84574e01f4e8d89100
97,515 shares@ SEK 235.150.015% mcap30.6% of flowAktieISIN SE0000872095FI:csv-4397a2950910a524d35e
Canonical exit: 28 Oct 2026 (T+90)
97,515 shares@ SEK 474.2560.031% mcap61.7% of flowAktieISIN SE0000872095FI:csv-d325c993227e4ce0fc1a
100,000 shares@ SEK 464.000.031% mcap19.6% of flowAktieISIN SE0000872095FI:csv-58629e5394c9e92ae259
100,000 shares@ SEK 235.150.016% mcap10.0% of flowAktieISIN SE0000872095FI:csv-5dced926b59f6a0677d6
Canonical exit: 28 Oct 2026 (T+90)
37,292 shares@ SEK 235.150.0059% mcap22.4% of flowAktieISIN SE0000872095FI:csv-1fee1526e5a8d8c0baa7
Canonical exit: 28 Oct 2026 (T+90)
100,000 shares@ SEK 457.400.031% mcap19.4% of flowAktieISIN SE0000872095FI:csv-3700241e2fa5f3f12862
100,000 shares@ SEK 235.150.016% mcap10.0% of flowAktieISIN SE0000872095FI:csv-50f21d0ebcde3c56cc35
Canonical exit: 27 Oct 2026 (T+90)
37,292 shares@ SEK 457.340.011% mcap43.5% of flowAktieISIN SE0000872095FI:csv-c9e632e20944582005e3
37,292 shares@ SEK 235.150.0059% mcap22.4% of flowAktieISIN SE0000872095FI:csv-e11729f2737e82c30a59
Canonical exit: 26 Oct 2026 (T+90)
10,050 shares@ SEK 456.790.0031% mcap11.7% of flowAktieISIN SE0000872095FI:csv-1915fbd0bec313c90432
66,702 shares@ SEK 235.150.011% mcap34.1% of flowAktieISIN SE0000872095FI:csv-3e1808fa0bee48e0cf39
Canonical exit: 26 Oct 2026 (T+90)
66,702 shares@ SEK 454.44390.020% mcap65.9% of flowAktieISIN SE0000872095FI:csv-3bdc92b515b6f5eb47f3
57,232 shares@ SEK 455.670.018% mcap48.8% of flowAktieISIN SE0000872095FI:csv-9f1665f9f78b3849460f
57,232 shares@ SEK 235.150.0090% mcap25.1% of flowAktieISIN SE0000872095FI:csv-6997cebafab9e7b5f0d6
Canonical exit: 20 Oct 2026 (T+90)
61,936 shares@ SEK 457.04720.019% mcap46.9% of flowAktieISIN SE0000872095FI:csv-f016de64ea4c3f364b85
61,936 shares@ SEK 235.150.0098% mcap24.1% of flowAktieISIN SE0000872095FI:csv-c581b4c1a89c672b00d4
Canonical exit: 19 Oct 2026 (T+90)
29,833 shares@ SEK 235.150.0047% mcap23.5% of flowAktieISIN SE0000872095FI:csv-cf7b2e4099f4170d4c5e
Canonical exit: 18 Oct 2026 (T+90)
29,833 shares@ SEK 235.150.0047% mcap23.5% of flowAktieISIN SE0000872095FI:csv-4836411cdeb9e7d50e79
Canonical exit: 14 Oct 2026 (T+90)
29,833 shares@ SEK 468.00130.0094% mcap46.8% of flowAktieISIN SE0000872095FI:csv-483ae21ec200e7e39e1a
4,000 shares@ SEK 468.66250.0013% mcap6.3% of flowAktieISIN SE0000872095FI:csv-01aa685cbb380fd07054
11,552 shares@ SEK 430.96440.0032% mcap6.7% of flowAktieISIN SE0000872095FI:csv-2a8e2d36d4a5943b66e0
27,262 shares0AktieISIN SE0000872095FI:csv-3c175778aea868597b4f
25 of 445 declarations
About Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum, a Swedish healthcare group listed in Stockholm (SEK 155.4 billion market capitalisation, 9.8% of the capital held by insiders), combines many purchases with heavier sales: 177 purchases worth EUR 76.7 million (median EUR 52,754) against 109 sales worth EUR 107.1 million (median EUR 415,231), so 62% purchases. Between May 13, 2024 and June 11, 2024, 10 insiders bought for EUR 19.1 million.
Guido Oelkers, chief executive officer, dominates both columns. In late July 2026 he sold EUR 4.2 million on July 28 and EUR 4.1 million on July 27, with another executive, Duane Barnes, selling EUR 4.2 million on the same July 28; he bought EUR 2.1 million on July 30, 2026, EUR 2.1 million on July 29, 2026 and EUR 2.1 million on June 3, 2024. He has 54 filings (30 purchases, 18 sales). Bo Jesper Hansen, chairman of the board, has 31 filings of which 30 are purchases; Milan Zdravkovic, chief medical officer, 22 of which 21.
Read moreShow less
Of 399 filings published between July 19, 2016 and August 17, 2026, 100 date from 2023 and 92 from 2024, against 14 in 2025. For 165 purchases a 90-day result is stored: a median of minus 2.4%, with 48% positive (recorded past results, not a forecast). Last twelve months: 52 filings, 23 purchases, 16 sales. Median delay: 2 days.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
